医学
心房颤动
内科学
心脏病学
回顾性队列研究
人口
置信区间
血管病学
队列
心肌病
队列研究
心力衰竭
优势比
入射(几何)
不利影响
收缩性
逻辑回归
比例危险模型
风险因素
变向性
危险系数
心电图
拜瑞妥
不良事件报告系统
风险评估
药物流行病学
肥厚性心肌病
随机对照试验
荟萃分析
心房扑动
相对风险
心脏外科
人口研究
四分位间距
作者
Lingqing Ding,Xinhang Liao,Yongkuan Yang,Congqin Chen,Jie Xiao
标识
DOI:10.1186/s12872-026-05699-8
摘要
BACKGROUND: Mavacamten is a novel selective cardiac myosin inhibitor indicated for patients with obstructive hypertrophic cardiomyopathy (oHCM). Given its negative inotropic properties, which theoretically reduce myocardial contractility and affect left atrial systolic function, concerns have arisen about its potential association with an increased incidence of atrial fibrillation (AF). The study aims to assess this potential association. METHODS: We employed a dual approach combining real-world data analysis and evidence synthesis. First, disproportionality and time-to-onset analyses were performed using the FDA Adverse Event Reporting System (FAERS) across two models: the general population (Model 1) and an HCM-specific cohort (Model 2). Independent risk factors for AF were identified using logistic regression. Second, a meta-analysis of placebo-controlled trials was conducted to evaluate the safety profile of mavacamten, with pooled risk ratios (RRs) and 95% confidence intervals (CIs) . RESULTS: In the disproportionality analysis, Model 1 revealed a signal for AF with mavacamten (adjusted ROR 18.54, 95% CI 11.53–29.80, P < 0.05; EB05 11.55). In contrast, no significant disproportionality signal was observed in Model 2 (aROR 4.28, 95% CI 1.30–14.07, P = 0.017; EB05 0.74). The time-to-onset analysis indicated a random failure type for AF occurrence in mavacamten-treated patients. The meta-analysis included five RCTs and one retrospective cohort study. Compared with placebo, mavacamten was not associated with an increased risk of AF (RR = 0.92, 95% CI 0.80–1.06, P = 0.12). CONCLUSION: Our findings did not identify a significant association between mavacamten and AF in patients with HCM. These results should be interpreted with caution due to the limited number of studies and small sample sizes.
科研通智能强力驱动
Strongly Powered by AbleSci AI